高密度脂蛋白模拟肽。

HDL Mimetic Peptides.

机构信息

The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.

McGill University, Montreal, QC, Canada.

出版信息

Adv Exp Med Biol. 2022;1377:141-151. doi: 10.1007/978-981-19-1592-5_11.

DOI:10.1007/978-981-19-1592-5_11

PMID:35575927

Abstract

Since therapeutic strategies designed to raise HDL failed to exert the expected effective cardiovascular disease (CVD) outcomes in clinical trials, how to improve HDL function rather than its plasma level has become a new focus of scientists' attention. Numerous HDL mimetic peptides have been designed and investigated in various animal models in recent years. Although the underlying mechanisms are not fully understood, the peptides' antiatherogenic effects, such as acceleration of RCT and improvement of natural HDL function without necessarily raising its level, showed a promising therapeutic role in the prevention of atherosclerosis and other diseases. This chapter reviews recent studies on the roles and potentials of HDL mimetic peptides in atherosclerosis-related CVD.

摘要

由于旨在提高 HDL 的治疗策略在临床试验中未能产生预期的有效心血管疾病 (CVD) 结果，如何改善 HDL 的功能而非其血浆水平已成为科学家关注的新焦点。近年来，许多 HDL 模拟肽已在各种动物模型中进行了设计和研究。尽管其潜在机制尚未完全阐明，但这些肽的抗动脉粥样硬化作用，如加速 RCT 和改善天然 HDL 功能而不一定提高其水平，在预防动脉粥样硬化和其他疾病方面显示出有前景的治疗作用。本章综述了 HDL 模拟肽在与动脉粥样硬化相关的 CVD 中的作用和潜力的最新研究。